Table 3.
2014-censored and lifetime survival benefits of the Brazilian national ART program for patients starting ART between 1997 and 2014
| 2014 censored results (LY) | Lifetime results (LY) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Era | A: Persons initiating ARTa | B: Per capita life expectancy, without ART | C: Per capita life expectancy, with ARTb | D: Per capita survival benefitc [C–B] | E: Survival benefit [A×D] | B’: Per capita life expectancy, without ARTd | C’: Per capita life expectancy, with ART | D’: Per capita survival benefit [C’-B’] | E’: Survival benefit [A×D’] |
| Era 1 (1997–1999) | 114,062 | 2.7 | 6.5 | 3.8 | 433,436 | 2.7 | 11.0 | 8.3 | 946,715 |
| Era 2 (2000–2003) | 115,363 | 3.2 | 8.1 | 4.9 | 565,279 | 3.3 | 17.5 | 14.2 | 1,638,155 |
| Era 3 (2004–2007) | 92,895 | 3.7 | 7.0 | 3.3 | 306,554 | 4.1 | 20.7 | 16.6 | 1,542,057 |
| Era 4 (2008–2012) | 189,741 | 3.3 | 4.3 | 1.0 | 189,741 | 4.9 | 23.0 | 18.1 | 3,434,312 |
| Era 5 (2013) | 43,755 | 1.8 | 1.9 | 0.1 | 4375 | 5.5 | 25.3 | 19.8 | 866,349 |
| Era 6 (2014) | 42,925 | 1.0 | 1.0 | 0.0* | 385 | 7.1 | 27.0 | 19.9 | 854,208 |
| Total | 598,741 | 1,499,770 | 9,281,796 | ||||||
Calculated as the number of patients on ART in the given era minus the patients still alive from previous eras
censored life expectancy for 1997 cohort is out of a possible 18 years whereas that for 2014 is out of a possible one year
calculated by subtracting life expectancies during 1997–2014 for the Without ART simulations (column B) from those for the ART simulations (column C). Survival gains in 1997 are thus measured over 18 years, whereas those in 2014 are measured over one year
increase in life expectancy without ART is due to an increase in CD4 count at presentation by era.
Value is non-zero but is reported as zero due to rounding.